Over the past 27 years I have had the privilege to lead large, cross-functional, cross-vendor teams in both Clinical Operations and Program Management delivering quality on highly complex immuno -oncology trials primarily but as well in other therapeutic areas (, inflammation, vaccines, anti-infectives), at different stages of development in a variety of companies ranging from small Biotech to large Global Pharma.
\nThrough these experiences, I have found that positive collaboration, open and honest communication, and alignment on team objectives is paramount to building a team that grows together and can weather storms that inevitably occur on complex, novel trials. I strive to incorporate these attributes in the teams that I work with. Most recently, I serve as the clinical lead for a novel immunotherapy compound , global lead for a pivotal Phill metastatic breast cancer trial, and product oversight (clinical operations) .
\nI feel grateful to work in a field that has such impact to patients with grie vous illnesses.<\/p>\n
l have excellent communication and influencing skills combined with leadership skills as a line manager as well as by leading multi-national and interdisciplinary teams and working as part of a matrix organization with broad international experience .<\/p>\n
I’m embedded into an active network of key opinion leaders from pharmaceutical industry, academia and regulatory agencies worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"
Over the past 27 years I have had the privilege to lead large, cross-functional, cross-vendor teams in both Clinical Operations and Program Management delivering quality on highly complex immuno -oncology trials primarily but as well in other therapeutic areas (, inflammation, vaccines, anti-infectives), at different stages of development in a variety of companies ranging from … <\/p>\n